Myopia Management and Presbyopia Correction Market By Treatment Area Myopia Management, Presbyopia Correction; By Myopia Correction and Management Product Single-Vision Spectacles, Single-Vision Soft Contact Lenses, Myopia-Control Spectacle Lenses, Soft Myopia-Control Contact Lenses, Orthokeratology Lenses, Specialty Contact Lenses, Low-Dose Atropine, Combination Myopia Management; By Presbyopia Correction Product Reading Glasses, Progressive Addition Lenses, Multifocal Contact Lenses, Daily Disposable Multifocal Lenses, Monovision Contact Lenses, Presbyopia Eye Drops, Premium Intraocular Lenses, Refractive Procedures; By Patient Age and Vision Need Children Aged 6–12, Teenagers Aged 13–17, Progressive Pediatric Myopia Patients, Contact-Lens-Suitable Pediatric Users, Adults Aged 40–50, Adults Aged 50–64, Adults Aged 65 and Above, Premium-Correction-Eligible Adults; By End User and Distribution Channel Independent Optometrists and Eye-Care Professionals, Optical Retail Chains, Specialty Lens Fitters, Ophthalmology and Surgical Centers, Online Optical and Digital Channels; By Revenue-Capture Layer Manufacturer Revenue, ECP and Fitting Revenue, Retail and End-User Spend; By Geography, Segment Revenue Estimation, Forecast, 2025–2035

Introduction and Strategic Context

The Global Myopia Management and Presbyopia Correction Market will witness a CAGR of 7.3%, rising from USD 22,900 million in 2025 to USD 46,200 million by 2035, confirms Strategic Market Research. The forecast follows a focused commercial boundary covering active myopia management and specialized presbyopia correction products while excluding general retail eyewear revenue without a clear clinical or premium correction role.

 

The market combines two large vision-care needs that differ in patient age, treatment goals, and buying behavior. Myopia management is centered on slowing the progression of nearsightedness, especially among children and teenagers. Presbyopia correction addresses the age-related decline in near vision that usually becomes noticeable after the age of 40. Together, these categories create a broad market spanning pediatric care, adult vision correction, recurring contact lens use, pharmaceutical treatment, and surgical intervention.

 

Myopia management is valued at USD 4,450 million in 2025 and is projected to reach USD 15,300 million by 2035, reflecting a CAGR of 13.1%. In contrast, presbyopia correction represents the larger revenue base. It is expected to grow from USD 18,450 million in 2025 to USD 30,900 million by 2035, at a CAGR of 5.3%. Myopia management’s share of the combined market is forecast to rise from 19.4% in 2025 to 33.1% in 2035. Presbyopia correction will remain the dominant category, but pediatric myopia control will account for a growing share of new revenue creation.

 

Several structural factors are shaping this outlook. Pediatric myopia is increasingly treated as a long-term clinical concern rather than a basic refractive error. Parents are becoming more willing to consider products that may slow progression, particularly where eye-care professionals provide clear evidence and structured follow-up. This is supporting demand for myopia-control soft contact lenses, specialized spectacle lenses, orthokeratology, low-dose atropine, and combined treatment approaches.

 

Presbyopia care is also changing. Standard reading glasses and progressive lenses still support a large portion of demand, but many adults now seek solutions that offer greater convenience, appearance, and freedom during work or daily activities. This shift is creating stronger commercial potential for multifocal contact lenses, presbyopia eye drops, premium intraocular lenses, and selected refractive procedures.

 

Technology and clinical evidence will remain central to competition. Pediatric products require strong safety records, clear age eligibility, and reliable long-term outcomes. Presbyopia solutions must improve near and intermediate vision without creating major compromises in comfort, distance vision, or adaptation. As a result, product performance alone is not enough. Practitioner confidence, fitting efficiency, patient education, and treatment retention will determine commercial success.

 

Key stakeholders include contact lens manufacturers, spectacle lens producers, pharmaceutical companies, ophthalmic device manufacturers, eye-care professionals, optical retailers, specialty lens fitters, regulators, investors, patients, and parents. Among these groups, eye-care professionals remain the main control point because they influence diagnosis, product recommendation, fitting, follow-up, and switching behavior.

 

The strongest long-term opportunity is the lifetime vision-care relationship. A child entering myopia management may later become a conventional contact lens user and eventually a multifocal wearer. Companies that retain patients across these stages can build recurring revenue rather than depend on one-time product sales.

 

Market Segmentation and Forecast Scope

The Myopia Management and Presbyopia Correction Market is assessed across treatment area, product modality, patient age, clinical need, distribution channel, revenue-capture layer, and geography. The forecast period runs from 2025 to 2035, with the market expanding from USD 22,900 million in 2025 to USD 46,200 million by 2035.

By Treatment Area

• Myopia Management: This segment covers active interventions intended to slow myopia progression, particularly among children and teenagers. It accounted for 19.4% of the market in 2025, with revenue forecast to rise from USD 4,450 million to USD 15,300 million by 2035 at a CAGR of 13.1%.

• Presbyopia Correction: This segment includes optical, pharmaceutical, and surgical solutions used to improve near and intermediate vision in aging adults. It represented 80.6% of the market in 2025 and is projected to increase from USD 18,450 million to USD 30,900 million by 2035, reflecting a CAGR of 5.3%.

 

By Myopia Correction and Management Product

• Single-Vision Spectacles: These lenses correct refractive error but do not actively slow myopia progression. They form the conventional entry point from which diagnosed patients may later move toward specialized myopia-control products.

• Single-Vision Soft Contact Lenses: This segment supports routine vision correction for teenagers and adults. It also creates a transition pathway into daily disposable, specialty, or myopia-control contact lenses.

• Myopia-Control Spectacle Lenses: These specialized lenses use structured optical designs to reduce myopia progression while correcting distance vision. Their familiar handling and lower perceived safety burden make them attractive for younger children and contact-lens-hesitant parents.

• Soft Myopia-Control Contact Lenses: This segment includes dual-focus and related soft lens technologies designed for pediatric progression control. Within the CooperVision-addressable pool, revenue is forecast to rise from USD 610 million in 2025 to USD 3,420 million by 2035, representing a CAGR of 18.8%.

• Orthokeratology Lenses: Ortho-k lenses temporarily reshape the cornea during overnight wear while supporting daytime vision without glasses. Adoption remains concentrated among specialty fitters because the modality requires careful fitting, regular monitoring, and strong patient compliance.

• Specialty Contact Lenses: This segment includes advanced lens designs used for patients requiring customized correction or more intensive myopia-management support. It benefits from premium pricing but depends heavily on practitioner expertise.

• Low-Dose Atropine: Low-dose atropine is a pharmacological approach used to slow pediatric myopia progression. Its role varies by country depending on prescribing practices, regulatory status, concentration protocols, and physician acceptance.

• Combination Myopia Management: This segment combines optical treatment with atropine or another intervention for patients showing rapid progression. It offers a more personalized pathway but raises monitoring requirements and treatment costs.

 

By Presbyopia Correction Product

• Reading Glasses: Readers provide a low-cost and accessible solution for near-vision difficulty. They remain a common first response among early presbyopes but offer limited correction for intermediate and distance vision.

• Progressive Addition Lenses: Progressive lenses provide near, intermediate, and distance correction within a single spectacle lens. Their established acceptance makes them a major substitute for multifocal contacts, particularly among patients prioritizing simplicity.

• Multifocal Contact Lenses: These lenses provide correction across several viewing distances and create recurring annual product revenue. Within the CooperVision-addressable pool, the segment is projected to expand from USD 2,460 million in 2025 to USD 4,900 million by 2035, at a CAGR of 7.1%.

• Daily Disposable Multifocal Lenses: This premium subsegment combines all-distance correction with convenience, hygiene, and lower maintenance. It is particularly relevant for existing contact lens users entering the early stages of presbyopia.

• Monovision Contact Lenses: Monovision corrects one eye mainly for distance and the other for near vision. It remains a practical ECP-led alternative, although adaptation and depth-perception limitations can restrict long-term use.

• Presbyopia Eye Drops: Prescription drops provide temporary near-vision improvement without spectacles or contact lenses. They are most relevant for early or occasional users and may operate as a bridge, add-on, or substitute depending on treatment duration and dosing preference.

• Premium Intraocular Lenses: Premium IOLs provide surgical correction for presbyopia, often alongside cataract treatment. They become more relevant among older patients seeking a longer-term solution and willing to undergo an invasive procedure.

• Refractive Procedures: This segment covers surgical or procedure-based approaches intended to reduce dependence on glasses or contact lenses. Adoption is shaped by patient eligibility, procedure cost, clinical risk, and expected visual outcomes.

 

By Patient Age and Vision Need

• Children Aged 6–12: This group represents the central screening and early-intervention pool for pediatric myopia. Early diagnosis is commercially important because treatment initiated during active eye growth may continue for several years.

• Teenagers Aged 13–17: Teenagers require progression monitoring along with lifestyle-oriented vision correction. They are more likely than younger children to accept contact lenses for school, sports, appearance, and daily convenience.

• Progressive Pediatric Myopia Patients: These patients show continuing refractive progression and represent the highest-priority group for active myopia management. Treatment decisions depend on progression speed, age, family history, and practitioner recommendation.

• Contact-Lens-Suitable Pediatric Users: This segment includes children who can safely manage soft lenses or ortho-k with parental support. It is the most direct pediatric revenue pool for contact lens manufacturers.

• Adults Aged 40–50: Early presbyopes often begin with occasional readers or continue using existing contact lenses. This creates an important conversion window for multifocal lenses and prescription eye drops.

• Adults Aged 50–64: These patients generally require more consistent near and intermediate correction. Multifocal contacts, progressive lenses, and premium optical products are particularly relevant within this age group.

• Adults Aged 65 and Above: Older presbyopes are more likely to enter cataract-linked treatment pathways. Premium IOLs and surgical correction become more relevant as natural-lens aging progresses.

• Premium-Correction-Eligible Adults: This segment includes patients with sufficient clinical suitability and willingness to pay for multifocal contacts, premium spectacles, pharmaceutical options, or surgical correction.

 

By End User and Distribution Channel

• Independent Optometrists and Eye-Care Professionals: Independent practices play a central role in diagnosis, product recommendation, fitting, follow-up, and retention. Their confidence has a direct effect on adoption across both pediatric myopia and presbyopia products.

• Optical Retail Chains: Retail chains provide broad patient access, standardized dispensing, and high-volume spectacle sales. Their scale can accelerate adoption of myopia-control spectacles, progressive lenses, and selected contact lens products.

• Specialty Lens Fitters: These professionals primarily support ortho-k, complex contact lenses, and customized myopia-management programs. Their expertise creates strong patient value, although limited practitioner capacity constrains mass adoption.

• Ophthalmology and Surgical Centers: Ophthalmologists manage pharmacological treatment, advanced clinical evaluation, refractive procedures, cataract-linked care, and premium IOL implantation. This channel is especially important for older presbyopes and complex pediatric cases.

• Online Optical and Digital Channels: Online channels support product replenishment, patient education, appointment generation, and selected eyewear purchases. Their role is stronger in repeat ordering than in initial specialty fitting or clinical product selection.

 

By Revenue-Capture Layer

• Manufacturer Revenue: This layer includes net revenue earned from lenses, eye drops, specialty products, surgical devices, and related technologies. It represents the most direct commercial measure for product manufacturers.

• ECP and Fitting Revenue: This segment covers consultation, fitting, monitoring, and follow-up services provided by optometrists, ophthalmologists, and specialty lens practices. It is particularly important in ortho-k and pediatric myopia-management programs.

• Retail and End-User Spend: This layer captures the final amount paid through optical stores, clinics, online channels, and surgical providers. It includes product markups, dispensing charges, service value, and channel margins.

 

By Geography

• Asia-Pacific: The region leads the market by revenue and pediatric myopia volume. It is projected to expand from USD 8,460 million in 2025 to USD 19,690 million by 2035, recording a CAGR of 8.8%.

• North America: North America benefits from high contact lens penetration, premium pricing, established ECP infrastructure, and early adoption of clinically validated products. Revenue is forecast to rise from USD 5,950 million in 2025 to USD 11,200 million by 2035, at a CAGR of 6.5%.

• Europe: Europe combines established progressive-lens demand with expanding multifocal contact lens and myopia-management adoption. The regional market is expected to increase from USD 6,250 million in 2025 to USD 10,650 million by 2035, reflecting a CAGR of 5.5%.

• Latin America: Growth is supported by improving access to private eye care, urban optical retail expansion, and rising premium correction demand. The market is projected to grow from USD 1,250 million in 2025 to USD 2,630 million by 2035, at a CAGR of 7.7%.

• Middle East and Africa: This region remains underpenetrated but offers selective opportunities in premium optical care, specialty clinics, and urban healthcare centers. Revenue is forecast to increase from USD 990 million in 2025 to USD 2,030 million by 2035, representing a CAGR of 7.4%.

The fastest commercial expansion is expected where clinical need, practitioner readiness, recurring product use, and patient willingness to pay overlap. Soft myopia-control lenses represent the strongest growth pathway, while multifocal contact lenses remain the most established recurring opportunity within presbyopia correction.

 

 

Market Trends and Innovation Landscape

The Myopia Management and Presbyopia Correction Market is moving away from basic vision correction toward clinically differentiated products that can slow disease progression, improve convenience, and support recurring patient relationships. Innovation between 2025 and 2035 will be shaped by optical design, daily disposable formats, pharmacological treatments, specialty fitting systems, digital practice tools, and combination-care pathways.

Soft Myopia-Control Lenses Are Becoming a Core Growth Platform

Dual-focus and related myopia-control soft lenses are gaining strategic importance because they combine progression management with daytime visual correction. The segment is projected to expand from USD 610 million in 2025 to USD 3,420 million by 2035, reflecting a CAGR of 18.8%. This makes it the fastest-growing product pool within the CooperVision-addressable opportunity.

Product development is increasingly focused on improving comfort, handling, optical stability, and daily disposable convenience. However, adoption still depends on whether parents believe their children can manage contact lenses safely. Eye-care professionals must also feel confident explaining the treatment and monitoring outcomes.

The next competitive step will not be a lens that simply works. It will be a lens system that is easy for practitioners to prescribe and easy for families to maintain.

 

Myopia-Control Spectacles Are Expanding Modality Competition

Specialized spectacle lenses are gaining traction because they resemble familiar eyewear and require less behavioral change than pediatric contact lenses or orthokeratology. The document identifies strong competitive pressure from platforms such as Essilor Stellest, HOYA MiYOSMART, and ZEISS MyoCare.

The 2025 authorization of Essilor Stellest spectacle lenses in the United States reinforces the move toward multi-modality pediatric myopia management. This development gives practitioners another clinically positioned option and increases the need for contact lens manufacturers to compete on lifestyle convenience, evidence quality, and recurring engagement.

 

Orthokeratology Is Retaining Its Premium Specialty Position

Orthokeratology remains an important option for children and teenagers who want clear daytime vision without spectacles or soft lenses. The combined orthokeratology and specialty lens revenue pool is forecast to rise from USD 790 million in 2025 to USD 1,760 million by 2035, at a CAGR of 8.3%.

Innovation is centered on more predictable fitting, corneal topography integration, improved lens design, and structured follow-up systems. Yet ortho-k remains difficult to scale because it requires specialist knowledge, longer chair time, and close monitoring. The model works best in high-value practices with established specialty lens capabilities.

 

Combination Myopia Management Is Emerging

Combination care brings together optical products and pharmacological treatment, most commonly specialty lenses or myopia-control spectacles used alongside low-dose atropine. It may become more relevant for children whose myopia continues to progress despite a single intervention.

This pathway allows treatment to be adjusted according to progression rate, age, family history, and tolerance. That said, it also increases clinical complexity. Practitioners need clearer protocols for patient selection, dosing, follow-up, and treatment duration.

Combination treatment could create a high-value clinical niche, but it is unlikely to become routine until monitoring standards are more consistent.

 

Multifocal Contact Lenses Are Shifting Toward Easier Fitting

Multifocal contact lenses remain the most direct recurring revenue opportunity in presbyopia correction. The segment is expected to increase from USD 2,460 million in 2025 to USD 4,900 million by 2035, representing a CAGR of 7.1%.

Innovation is increasingly focused on improving near, intermediate, and distance vision without creating unacceptable compromises in comfort or adaptation. Daily disposable multifocal formats are also gaining strategic value because they offer hygiene, convenience, and premium pricing. Digital fitting aids and standardized selection protocols may further reduce trial-and-error during the initial fitting process.

 

Presbyopia Eye Drops Are Creating a New Treatment Pathway

Prescription eye drops are introducing a non-spectacle and non-contact-lens option for early presbyopes. Their appeal lies in temporary near-vision improvement without requiring permanent changes to eyewear habits.

The leading development focus is expected to remain on treatment duration, dosing frequency, visual quality, side-effect management, and repeat-use behavior. These products may compete with multifocal contact lenses for occasional users, but they may also be used as an add-on solution rather than a complete replacement.

 

Digital Tools Are Becoming Part of Product Innovation

Digital calculators, fitting aids, patient education platforms, renewal reminders, and outcome-tracking tools are becoming more important across both myopia and presbyopia care. The document identifies digital fitting support as a high-priority commercial lever because it can improve consistency, reduce chair-time variability, and lower abandonment risk.

The market is therefore evolving from individual products into connected care programs. Manufacturers that combine clinical evidence, practitioner training, patient education, and retention support will be better placed to convert innovation into sustained revenue.

 

 

Competitive Intelligence and Benchmarking

Competition in the Myopia Management and Presbyopia Correction Market is increasingly defined by modality rather than company size alone. Contact lens manufacturers compete for recurring pediatric and adult users. Spectacle lens companies are strengthening their position in myopia control. Specialty lens providers remain influential in orthokeratology. Pharmaceutical and surgical companies are also creating new alternatives for presbyopia correction. The leading competitive set includes CooperVision, Johnson & Johnson Vision, Alcon, Bausch + Lomb, EssilorLuxottica, HOYA Vision Care, and ZEISS Vision Care.

CooperVision

CooperVision holds a differentiated position across soft myopia-control lenses, multifocal contact lenses, daily disposable products, and specialty lens pathways. Its competitive strength is closely linked to eye-care professional relationships and its ability to support patients across several life stages.

The company received a competitive presence score of 4.5 in the United States, 3.0 in China, 3.8 in Japan, and 3.6 in Germany. Its strongest near-term opportunities are pediatric soft-lens adoption, multifocal conversion, and daily disposable premiumization. The company’s addressable multifocal contact lens pool is projected to reach USD 4,900 million by 2035, while the daily disposable multifocal premium opportunity is estimated at USD 1,850 million.

 

Johnson & Johnson Vision

Johnson & Johnson Vision is one of the strongest competitors in mature contact lens markets. Its broad contact lens portfolio, practitioner access, and established position in daily disposable and multifocal correction support strong visibility across North America, Europe, and Japan.

Its competitive presence scores stand at 4.5 in the United States, 3.8 in China, 4.2 in Japan, and 3.8 in Germany. The company is particularly relevant in presbyopia because it competes directly for existing contact lens users moving toward multifocal products.

 

Alcon

Alcon combines contact lens exposure with a substantial position in premium intraocular lenses and surgical presbyopia correction. This gives the company access to both early-stage contact lens users and older patients entering cataract-linked treatment pathways.

Its competitive presence is scored at 4.3 in the United States, 3.7 in China, 4.0 in Japan, and 3.7 in Germany. Alcon’s surgical adjacency is an important differentiator because premium lens procedures become more relevant as patients age beyond routine contact lens use.

 

Bausch + Lomb

Bausch + Lomb remains part of the core multifocal contact lens competitive group. Its strength lies in established practitioner relationships, broad corrective lens exposure, and presbyopia-focused contact lens options.

The company scores 4.0 in the United States, 3.2 in China, 3.5 in Japan, and 3.3 in Germany. Its competitive position is solid in mature markets, although it faces pressure from premium daily disposable portfolios and stronger myopia-management differentiation.

 

EssilorLuxottica

EssilorLuxottica is a major competitive force in spectacle-based myopia management and progressive presbyopia correction. Its optical retail reach and spectacle lens scale make it a strong substitute competitor to contact lens manufacturers.

The company records presence scores of 4.2 in the United States, 4.7 in China, 4.3 in Japan, and 4.5 in Germany. Its position strengthened further after the 2025 authorization of a myopia-control spectacle lens in the United States. This increased competitive pressure on pediatric soft contact lens pathways.

 

HOYA Vision Care

HOYA Vision Care has built strong recognition in pediatric myopia management through specialized spectacle lens technology and an extensive clinical evidence base. Its strategy is especially effective among families that prefer a familiar spectacle-based treatment.

HOYA’s competitive scores reach 3.6 in the United States, 4.6 in China, 4.8 in Japan, and 4.0 in Germany. Its strongest position is in Asia where practitioner familiarity and parental acceptance of myopia-control spectacles are relatively high.

 

ZEISS Vision Care

ZEISS Vision Care competes through premium spectacle lenses, optical expertise, and strong European channel credibility. Its role spans pediatric myopia-management products and adult progressive correction.

The company scores 3.0 in the United States, 4.0 in China, 3.6 in Japan, and 4.8 in Germany, making Germany its strongest market among the countries assessed. Its competitive advantage is most visible in premium optical environments where practitioner recommendation and lens quality carry substantial weight.

 

The competitive battle is no longer limited to one contact lens brand replacing another. Companies are competing to control the patient’s preferred modality. CooperVision’s strongest defence is therefore an integrated practitioner-led pathway that connects pediatric myopia management, adult contact lens retention, and later multifocal conversion.

 

Regional Landscape and Adoption Outlook

Regional adoption in the Myopia Management and Presbyopia Correction Market is shaped by pediatric myopia prevalence, contact lens acceptance, eye-care professional capacity, affordability, regulatory readiness, and access to premium optical products. Asia-Pacific offers the largest patient-volume opportunity, while North America and Europe provide stronger near-term monetization through established practitioner networks and higher annual spending per user.

North America

The North American market is projected to increase from USD 5,950 million in 2025 to USD 8,180 million in 2030 and USD 11,200 million by 2035, reflecting a CAGR of 6.5%. The region benefits from strong optometrist participation, broad contact lens familiarity, premium pricing, and relatively developed pathways for pediatric myopia management.

The United States is the regional leader, with revenue forecast to rise from USD 5,300 million in 2025 to USD 9,850 million by 2035. Presbyopia correction remains the larger revenue base, but myopia management is expected to expand at a CAGR of 14.9%. The most attractive white-space areas include multifocal contact lens conversion, practitioner-led pediatric programs, and daily disposable premiumization. Canada offers a smaller but structured opportunity through organized eye-care channels and growing clinical awareness.

Regulatory clarity supports the availability of clinically positioned products, but adoption still depends on practitioner training and parent willingness to pay. North America is less about creating demand from scratch and more about converting existing patients into higher-value treatment pathways.

 

Europe

The European market is forecast to grow from USD 6,250 million in 2025 to USD 8,130 million in 2030 and USD 10,650 million by 2035, representing a CAGR of 5.5%. Europe combines mature progressive-lens demand with gradually expanding adoption of multifocal contacts and pediatric myopia-control products.

Germany is one of the region’s most important markets, increasing from USD 1,320 million in 2025 to USD 2,260 million by 2035. The United Kingdom, France, Italy, Spain, and the Nordic countries also offer opportunities, although adoption rates differ according to practitioner behavior, product availability, pricing, and reimbursement structures.

The region’s main strength is its organized eye-care infrastructure. Still, commercial execution remains country-specific. Multifocal upgrades, premium daily disposable formats, and ECP-led myopia-management programs represent the clearest opportunities. Underserved areas are more visible where specialist fitting capacity is limited or patients continue to rely mainly on conventional spectacles.

 

Asia-Pacific

The Asia-Pacific market is expected to expand from USD 8,460 million in 2025 to USD 13,000 million in 2030 and USD 19,690 million by 2035, making it the fastest-growing region at a CAGR of 8.8%. Its leadership is supported by a large pediatric myopia burden, particularly in urban areas across China, Japan, South Korea, and Singapore.

China is the largest country-level growth engine. Its market is projected to rise from USD 4,250 million in 2025 to USD 11,600 million by 2035, reflecting a CAGR of 10.6%. Myopia management revenue alone is forecast to reach USD 6,100 million by 2035. However, spectacle lenses and orthokeratology already hold strong positions, so soft contact lens growth will require practitioner education, parent confidence, and localized fitting support.

Japan offers a mature specialty lens and premium presbyopia market. South Korea, Singapore, and Australia provide attractive conditions for high-value contact lens adoption, while India and selected Southeast Asian countries represent longer-term white space. Affordability, uneven access to trained eye-care professionals, and lower premium-product penetration may slow conversion in these emerging markets.

Asia-Pacific has the largest revenue ceiling, but it also requires the greatest level of market education and channel localization.

 

Latin America

The Latin American market is projected to grow from USD 1,250 million in 2025 to USD 1,840 million in 2030 and USD 2,630 million by 2035, at a CAGR of 7.7%. Brazil and Mexico are expected to lead regional demand due to their large urban populations, expanding private eye-care networks, and rising interest in premium optical correction.

The main opportunity lies in urban clinics and optical chains capable of supporting specialty fitting and follow-up. However, uneven disposable income, limited insurance coverage, and lower practitioner density outside major cities may restrict broad adoption. White space remains substantial in multifocal contact lenses and structured pediatric myopia-management programs.

 

Middle East and Africa

The Middle East and Africa market is expected to rise from USD 990 million in 2025 to USD 1,450 million in 2030 and USD 2,030 million by 2035, representing a CAGR of 7.4%. The GCC countries offer the strongest premium opportunity through private clinics, specialist hospitals, and higher consumer spending.

Across the wider African market, adoption remains constrained by limited ECP access, affordability pressures, and uneven product availability. This creates opportunities for practitioner training, distributor partnerships, affordable lens programs, and scalable patient-education models.

 

The regional opportunity is highly selective. Premium urban centers can support advanced products today, while broader market development will depend on access, education, and lower-cost delivery models.

 

End-User Dynamics and Use Case

End-user adoption in the Myopia Management and Presbyopia Correction Market is controlled by a mix of clinical suitability, patient age, practitioner confidence, treatment cost, and willingness to continue long-term care. Unlike routine eyewear, active myopia management and advanced presbyopia correction require diagnosis, product selection, fitting, education, and follow-up. This makes eye-care professionals the main commercial gateway.

Independent Optometrists and Eye-Care Professionals

Independent optometrists are the primary adopters of soft myopia-control lenses, multifocal contact lenses, progressive lenses, and structured monitoring programs. They assess eligibility, explain modality choices, manage fitting, and influence whether patients remain on treatment.

A progressive pediatric myopia patient can generate an estimated annual practice value of USD 520–950, while an early presbyopic contact lens wearer may generate USD 240–540 through fitting, follow-up, and annual renewal. Adoption is strongest where practices can control chair time and standardize patient communication.

 

Pediatric Eye-Care Specialists

Pediatric eye-care specialists manage children with early-onset, progressive, or high-risk myopia. They are more likely to use structured treatment plans that compare soft myopia-control lenses, specialized spectacles, orthokeratology, low-dose atropine, and combination approaches.

Their recommendation is heavily influenced by evidence quality, treatment age, progression rate, parental confidence, and the child’s ability to handle contact lenses. Planning estimates in the supplied document place recommendation likelihood at 52% for soft myopia-control lenses and 68% for myopia-control spectacles, reflecting the lower handling burden associated with spectacles.

 

Specialty Contact Lens and Orthokeratology Fitters

Specialty fitters support orthokeratology and customized contact lens pathways. These practices can capture high annual value because treatment requires corneal assessment, precise fitting, lens replacement, and repeated follow-up.

An orthokeratology pediatric patient may create annual ECP value of approximately USD 1,250–2,300. However, the pathway has high chair-time intensity and workflow complexity. So, it is commercially attractive but difficult to scale without trained staff and efficient monitoring systems.

 

Ophthalmologists and Surgical Centers

Ophthalmologists participate in complex pediatric diagnosis, atropine-based treatment, presbyopia eye-drop prescribing, cataract assessment, and premium intraocular lens procedures. Their role becomes more important when patients require pharmacological or surgical intervention rather than routine optical correction.

In presbyopia care, surgical centers mainly serve mature patients with cataract-linked vision needs. Premium intraocular lenses offer a higher-value but episodic revenue pathway, unlike contact lenses that generate recurring annual sales.

 

Optical Retail Chains

Optical retail chains provide broad access to reading glasses, progressive lenses, myopia-control spectacles, and selected contact lens products. Their scale supports standardized product education and wider geographic availability.

Retail chains are particularly influential among patients who prefer familiar spectacle-based correction. However, advanced contact lens pathways still require clinical fitting and cannot be managed as simple over-the-counter transactions.

 

Online Optical and Digital Platforms

Digital channels are primarily used for education, appointment scheduling, replenishment, subscription management, and renewal reminders. They can improve retention among established contact lens users, but they play a smaller role during initial pediatric fitting or complex presbyopia assessment.

Digital platforms create the most value after clinical selection has occurred. They support continuity but do not replace the practitioner’s role in diagnosis, fitting, or treatment switching.

 

Parents of Children with Myopia

Parents are both purchasers and treatment decision-makers. Their willingness to adopt active management depends on safety perception, annual cost, expected benefit, handling requirements, and confidence in the practitioner.

The main conversion barrier is often behavioral rather than clinical. Parents may accept specialized spectacles before contact lenses because the product feels more familiar. Clear education and early handling support are therefore essential for soft-lens adoption.

 

Adult Presbyopia Patients

Early presbyopes often begin with reading glasses because they are inexpensive and easy to use. Existing contact lens wearers are more likely to convert into multifocal lenses, particularly when they want continuous near, intermediate, and distance vision.

The supplied planning view places multifocal contact lens recommendation likelihood at 58%, but retention depends on fitting success, comfort, expectation setting, and visual satisfaction.

 

Illustrative Use Case

A contact lens-focused optometry practice in the United States identifies progressive myopia in a 10-year-old child. The optometrist explains spectacle, soft-lens, and orthokeratology options to the parents, then selects a daily disposable myopia-control lens based on handling ability and lifestyle. A structured follow-up schedule is created to assess vision, lens use, comfort, and progression.

This workflow improves consistency in parent education and reduces the risk of treatment abandonment. It also allows the practice to build a long-term relationship that may continue into teenage contact lens use and later adult vision correction. The commercial value comes from retention across life stages rather than from the initial fitting alone.

 

Recent Developments + Opportunities & Restraints

The Myopia Management and Presbyopia Correction Market has entered a more competitive phase as contact lenses, specialty spectacles, prescription eye drops, orthokeratology, and surgical solutions increasingly target the same patient decision points. Recent activity has been concentrated around regulatory approvals, new treatment modalities, daily disposable premiumization, and stronger eye-care professional support.

Recent Developments

• Essilor Stellest Received U.S. FDA Authorization in 2025: The authorization of Essilor Stellest spectacle lenses for slowing pediatric myopia progression formally strengthened spectacle-based myopia control in the United States. It also increased substitution pressure on pediatric soft contact lenses, particularly among younger children and parents who prefer a familiar spectacle format.

• Presbyopia Eye Drops Expanded the Non-Surgical Treatment Set: Prescription products such as Qlosi, VIZZ, and Yuvezzi have widened the treatment pathway for adults seeking temporary near-vision improvement without readers or contact lenses. The category is forecast to rise from USD 210 million in 2025 to USD 1,620 million by 2035, representing a CAGR of 22.7%.

• Daily Disposable Multifocal Products Gained Greater Strategic Importance: CooperVision’s MyDay multifocal has strengthened the premium daily disposable pathway for presbyopes seeking convenience and vision across near, intermediate, and distance ranges. Biofinity multifocal continues to support the reusable multifocal segment, creating a broader upgrade route for existing adult contact lens users.

• Myopia Management Became a Broader Modality Competition: MiSight 1 day, HOYA MiYOSMART, Essilor Stellest, Menicon Bloom, orthokeratology, and low-dose atropine now compete across different pediatric age groups and parent preferences. The competitive question is no longer whether active myopia management will grow. It is which modality will capture the child first and retain the patient over time.

• ECP Workflow Support Emerged as a Commercial Differentiator: Digital fitting aids, staff training, parent education materials, standardized follow-up programs, and retention tools are becoming part of the product proposition. These tools can reduce fitting friction and help practices manage chair time more efficiently.

 

Opportunities

• Soft Myopia-Control Contact Lens Expansion: The segment is projected to increase from USD 610 million in 2025 to USD 3,420 million by 2035, reflecting a CAGR of 18.8%. The strongest opportunity lies among contact-lens-suitable children whose parents require reassurance around safety, handling, and treatment continuity.

• Combination Myopia Management: Combined optical and pharmacological approaches are forecast to rise from USD 210 million in 2025 to USD 1,580 million by 2035, at a CAGR of 22.4%. This pathway may be particularly relevant for children with rapid progression or an inadequate response to one treatment modality.

• Multifocal Conversion and Lifecycle Retention: Converting existing or lapsed adult contact lens users into multifocal products represents a lower-friction opportunity than targeting the entire reader and progressive-lens population. Improved lifecycle retention across pediatric, teenage, adult, and presbyopic stages could generate an additional USD 2,370 million to USD 4,460 million in long-term CooperVision-relevant revenue.

• Country-Level White Space: By 2035, the estimated white-space opportunity reaches USD 1,720 million in China, USD 1,460 million in the United States, USD 640 million in Japan, and USD 390 million in Germany. China offers the largest scale opportunity, while the United States provides the strongest near-term conversion environment.

 

Restraints

• Parent Acceptance and Pediatric Handling Concerns: Soft myopia-control lenses require more education than spectacles. Safety perception, child maturity, handling ability, and annual cost can delay adoption even when a child is clinically eligible.

• ECP Training and Chair-Time Pressure: Orthokeratology, pediatric soft-lens fitting, and multifocal contact lens conversion require practitioner time and follow-up. Adoption may remain concentrated in specialist practices unless manufacturers simplify fitting, monitoring, and renewal workflows.

• Strong Modality Substitution: Myopia-control spectacles can capture younger patients before they enter contact lens pathways. In presbyopia, readers, progressive lenses, prescription drops, and premium intraocular lenses compete at different stages of the patient journey.

• Regulatory and Prescribing Variation: Low-dose atropine, prescription eye drops, and pediatric myopia-control products face different approval, prescribing, and availability conditions by country. This limits the use of one standardized global commercialization strategy.

 

The largest opportunity is not attached to one product alone. It comes from reducing patient leakage between diagnosis, active treatment, contact lens continuation, and later multifocal conversion.

 

Myopia Management and Presbyopia Correction Market Report Coverage Table

Report Attribute	Details
Forecast Period	2025 – 2035
Market Size Value in 2025	USD 22,900 Million
Revenue Forecast in 2035	USD 46,200 Million
Overall Growth Rate	CAGR of 7.3% (2025 – 2035)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2025 – 2035)
Segmentation	By Treatment Area, By Myopia Correction and Management Product, By Presbyopia Correction Product, By Patient Age and Vision Need, By End User and Distribution Channel, By Revenue-Capture Layer, By Geography
By Treatment Area	Myopia Management, Presbyopia Correction
By Myopia Correction and Management Product	Single-Vision Spectacles, Single-Vision Soft Contact Lenses, Myopia-Control Spectacle Lenses, Soft Myopia-Control Contact Lenses, Orthokeratology Lenses, Specialty Contact Lenses, Low-Dose Atropine, Combination Myopia Management
By Presbyopia Correction Product	Reading Glasses, Progressive Addition Lenses, Multifocal Contact Lenses, Daily Disposable Multifocal Lenses, Monovision Contact Lenses, Presbyopia Eye Drops, Premium Intraocular Lenses, Refractive Procedures
By Patient Age and Vision Need	Children Aged 6–12, Teenagers Aged 13–17, Progressive Pediatric Myopia Patients, Contact-Lens-Suitable Pediatric Users, Adults Aged 40–50, Adults Aged 50–64, Adults Aged 65 and Above, Premium-Correction-Eligible Adults
By End User and Distribution Channel	Independent Optometrists and Eye-Care Professionals, Optical Retail Chains, Specialty Lens Fitters, Ophthalmology and Surgical Centers, Online Optical and Digital Channels
By Revenue-Capture Layer	Manufacturer Revenue, ECP and Fitting Revenue, Retail and End-User Spend
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Singapore, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising pediatric myopia prevalence, increasing adoption of active myopia-control solutions, growing demand for premium vision correction, expansion of multifocal contact lenses, advancements in optical designs and pharmaceutical therapies, increasing eye-care professional awareness
Customization Option	Available upon request